Show simple item record

dc.contributor.authorPriest, Kelsey C
dc.contributor.authorGorfinkel, Lauren
dc.contributor.authorKlimas, Jan
dc.contributor.authorJones, Andrea A
dc.contributor.authorFairbairn, Nadia
dc.contributor.authorMcCarty, Dennis
dc.date.accessioned2019-03-20T09:38:20Z
dc.date.available2019-03-20T09:38:20Z
dc.date.issued2019-02-11
dc.identifier.issn1873-4758
dc.identifier.pmid30765118
dc.identifier.doi10.1016/j.drugpo.2019.01.020
dc.identifier.urihttp://hdl.handle.net/10147/624134
dc.description.abstractCanada and the United States (U.S.) face an opioid use disorder (OUD) and opioid overdose epidemic. The most effective OUD treatment is opioid agonist therapy (OAT)-buprenorphine (with and without naloxone) and methadone. Although federal approval for OAT occurred decades ago, in both countries, access to and use of OAT is low. Restrictive policies and complex regulations contribute to limited OAT access. Through a non-systematic literature scan and a review of publicly available policy documents, we examined and compared OAT policies and practice at the federal (Canada vs. U.S.) and local levels (British Columbia [B.C.] vs. Oregon). Differences and similarities were noted between federal and local OAT policies, and subsequently OAT access. In Canada, OAT policy control has shifted from federal to provincial authorities. Conversely, in the U.S., federal authorities maintain primary control of OAT regulations. Local OAT health insurance coverage policies were substantively different between B.C. and Oregon. In B.C., five OAT options were available, while in Oregon, only two OAT options were available with administrative limitations. The differences in local OAT access and coverage policies between B.C. and Oregon, may be explained, in part, to the differences in Canadian and U.S. federal OAT policies, specifically, the relaxation of special federal OAT regulatory controls in Canada. The analysis also highlights the complicating contributions, and likely policy solutions, that exist within other drug policy sub-domains (e.g., the prescription regime, and drug control regime) and broader policy domains (e.g., constitutional rights). U.S. policymakers and health officials could consider adopting Canada's regulatory policy approach to expand OAT access to mitigate the harms of the ongoing opioid overdose epidemic.
dc.language.isoenen_US
dc.subjectBuprenorphineen_US
dc.subjectDrug policyen_US
dc.subjectMethadoneen_US
dc.subjectOpioid agonist therapyen_US
dc.subjectOpioid use disorderen_US
dc.subjectbuprenorphine/naloxoneen_US
dc.subjectDRUGS MISUSEen_US
dc.subjectADDICTIONen_US
dc.subjectOPIOIDSen_US
dc.titleComparing Canadian and United States opioid agonist therapy policies.en_US
dc.source.journaltitleThe International journal on drug policy


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
pre-publication_Priest_Final_S ...
Size:
266.2Kb
Format:
PDF
Description:
pre-publication

This item appears in the following Collection(s)

Show simple item record